Cost-effectiveness of omalizumab for the treatment of severe pediatric allergic asthma-Results of a real-life study in Spain.
ICER
biologics
cost
omalizumab
pharmacoeconomics
severe pediatric allergic asthma
Journal
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038
Titre abrégé: Pediatr Allergy Immunol
Pays: England
ID NLM: 9106718
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
27
02
2023
received:
23
04
2023
accepted:
06
03
2023
medline:
28
4
2023
pubmed:
27
4
2023
entrez:
27
4
2023
Statut:
ppublish
Résumé
Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost-effective. A sample of 426 children with SPAA from the ANCHORS (Asthma iN CHildren: Omalizumab in Real-life in Spain) study was used to calculate the incremental cost-effectiveness ratio (ICER) for the avoidance of moderate-to-severe exacerbations (MSE) and also for the improvement in childhood Asthma Control Test (c-ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data on health encounters and drug consumption before and up to 6 years after the beginning of the treatment with omalizumab. The ICER per avoided MSE was €2107 after 1 year, and it consistently decreased to €656 in those followed up to 6 years. Similarly, the ICER for the minimally important difference in control tests showed a decrease from €2059 to €380 per each 0.5 points of improvement in ACQ5 and from €3141 to €2322 per each 3 points improvement in c-ACT, at years 1 and 6, respectively. The use of OMZ is a cost-effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.
Sections du résumé
BACKGROUND
Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost-effective.
METHODS
A sample of 426 children with SPAA from the ANCHORS (Asthma iN CHildren: Omalizumab in Real-life in Spain) study was used to calculate the incremental cost-effectiveness ratio (ICER) for the avoidance of moderate-to-severe exacerbations (MSE) and also for the improvement in childhood Asthma Control Test (c-ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data on health encounters and drug consumption before and up to 6 years after the beginning of the treatment with omalizumab.
RESULTS
The ICER per avoided MSE was €2107 after 1 year, and it consistently decreased to €656 in those followed up to 6 years. Similarly, the ICER for the minimally important difference in control tests showed a decrease from €2059 to €380 per each 0.5 points of improvement in ACQ5 and from €3141 to €2322 per each 3 points improvement in c-ACT, at years 1 and 6, respectively.
CONCLUSION
The use of OMZ is a cost-effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.
Substances chimiques
Omalizumab
2P471X1Z11
Anti-Asthmatic Agents
0
spiropentaneacetic acid
14364-43-3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13942Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
GINA committee. Global strategy for asthma management and prevention 2022 update. Global Initiative for Asthma. 2022. p. 225. http://www.ginasthma.org. Accessed November 4, 2022.
Van Den Akker-Van Marle ME, Bruil J, Detmar SB. Evaluation of cost of disease: assessing the burden to society of asthma in children in the European Union. Allergy. 2005;60(2):140-149.
CIHI. Asthma Hospitalizations Among Children and Youth in Canada: Trends and Inequalities - Chartbook 2018. https://www.cihi.ca/sites/default/files/document/asthma-hospitalization-children-2018-chartbook-en-web.pdf. Accessed November 4, 2022.
Pamuk G, Le Bourgeois M, Abou Taam R, de Blic J, Delacourt C, Lezmi G. The economic burden of severe asthma in children: a comprehensive study. J Asthma. 2021;58(11):1467-1477.
Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327-337.
Ferrante G, La Grutta S. The burden of pediatric asthma. Front Pediatr. 2018;6:1-7.
Perry R, Braileanu G, Palmer T, Stevens P. The economic burden of pediatric asthma in the United States: literature review of current evidence. Pharmacoeconomics. 2019;37(2):155-167.
Ahmed H, Turner S. Severe asthma in children- a review of definitions, epidemiology, and treatment options in 2019. Pediatr Pulmonol. 2019;54(6):778-787.
Blasco Bravo AJ, Perez-Yarza EG, Lazaro y de Mercado P, Bonillo Perales A, Diaz Vazquez CA, Moreno Galdo A. Coste del asma en pediatria en España: un modelo de evaluacion de costes basado en la prevalencia. An Esp Pediatr. 2011;74(3):145-153.
Chipps BE, Haselkorn T, Rosén K, Mink DR, Trzaskoma BL, Luskin AT. Asthma exacerbations and triggers in children in TENOR: impact on quality of life study. J Allergy Clin Immunol Pract. 2018;6(1):169-176.e2.
Cano-Garcinuño A, Bercedo-Sanz A, Mora-Gandarillas I, et al. Association between quality of life in parents and components of asthma control in children. J Asthma. 2014;51(10):1089-1095.
Just J, Deschildre A, Lejeune S, Amat F. New perspectives of childhood asthma treatment with biologics. Pediatr Allergy Immunol. 2019;30(2):159-171.
Palomares O, Sanchez-Ramon S, Davila I, et al. dIvergEnt: how IgE axis contributes to the continuum of allergic asthma and anti-IgE therapies. Int J Mol Sci. 2017;18(6):1-14.
Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108(2):E36.
Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-1216.
Busse W, Morgan W, Gergen P, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005-1015.
Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42(5):1224-1233.
Deschildre A, Marguet C, Langlois C, et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J. 2015;46(3):856-859.
Licari A, Castagnoli R, Denicolo C, et al. Omalizumab in children with severe allergic asthma: the italian real-life experience. Curr Respir Med Rev. 2017;13:36-42.
Brodlie M, McKean MC, Moss S, Spencer DA. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child. 2012;97(7):604-609.
Szefler SJ, Zeiger RS, Haselkorn T, et al. Economic burden of impairment in children with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2011;107(2):110-119.e1.
Chen W, Tavakoli H, FitzGerald JM, Subbarao P, Turvey SE, Sadatsafavi M. Age trends in direct medical costs of pediatric asthma: a population-based study. Pediatr Allergy Immunol. 2021;32(6):1374-1377.
Nieto Garcia A, Garriga-Baraut T, Plaza Martin AM, et al. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma. Pediatr Allergy Immunol. 2021;32(5):980-991.
Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the asthma control test. J Allergy Clin Immunol. 2009;124(4):719-23.e1.
Juniper EF, Svensson K, Mörk A-C, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99(5):553-558.
The Faustino Orgegozo Foundation. Estudios, tablas y gráficas de crecimiento.Accessed November 6, 2022.http://www.fundacionorbegozo.com/product-showcase/tablas/
Spanish General Council of Official Associations of Pharmacists. https://botplusweb.portalfarma.com. Accessed November 6, 2022.
Head of State of Spain. Extraordinary measures to reduce the public deficit - Amended by the Royal Decree-Law 9/2011. BOE-A-2010-8228 - BOE-A-2011-14021. 2010. p. 4-56. https://www.boe.es/eli/es/rdl/2010/05/20/8/con. Accessed November 6, 2022.
Vennera MDC, Sabadell C, Picado C. Duration of the efficacy of omalizumab after treatment discontinuation in “real life” severe asthma. Thorax. 2018;73(8):782-784.
Entrenas Costa LM, Casas-Maldonado F, Soto Campos JG, et al. Economic impact and clinical outcomes of omalizumab add-on therapy for patients with severe persistent asthma: a real-world study. Pharmacoecon Open. 2019;3(3):333-342.
Martinez-Moragon E, Climent M, Chiner E, Fernandez-Aracil C, Sanchez-Toril F, Lluch-Tortajada I. Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice. Farm Hosp. 2019;43(3):101-109.
Arrobas A, Barbosa MP, Rabiais S, Vandewalle B, Felix J. Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients. Pulmonology. 2021;27(2):124-133.
Levy AN, Garcia A Ruiz AJ, Garcia-Agua Soler N, MVH S. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma. 2015;52(2):205-210.
Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma. 2012;49(8):843-848.
Zhou H, Lu Y, Wu B, Che D. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children. J Asthma. 2020;57(1):87-94.
Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Cost-utility of omalizumab for the treatment of uncontrolled moderate-to-severe persistent pediatric allergic asthma in a middle-income country. Pediatr Pulmonol. 2021;56(9):2987-2996.
Sullivan PW, Li Q, Bilir SP, et al. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States. Curr Med Res Opin. 2020;36(1):23-32.
Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: results from the asthma policy model. J Allergy Clin Immunol. 2007;120(5):1146-1152.
Canonica GW, Colombo GL, Rogliani P, et al. Omalizumab for severe allergic asthma treatment in Italy: a cost-effectiveness analysis from PROXIMA study. Risk Manag Healthc Policy. 2020;13:43-53.
De Cock E, Miravitlles M, Gonzalez-Juanatey JR, Azanza-Perea JR. Threshold value of the cost for life-years gained by adopting health technologies in Spain: evidence from a literature review. Pharmacoeconomics. 2007;4(3):97-107.
Shaker M, Briggs A, Dbouk A, Dutille E, Oppenheimer J, Greenhawt M. Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab. J Allergy Clin Immunol Pract. 2020;8(2):565-572.